Praxis Investment Management Inc. Purchases Shares of 6,810 Hims & Hers Health, Inc. (NYSE:HIMS)

Praxis Investment Management Inc. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,810 shares of the company's stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Summit Securities Group LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at $38,000. UMB Bank n.a. increased its stake in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after buying an additional 961 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80. Following the completion of the transaction, the chief executive officer now owns 89,311 shares of the company's stock, valued at $5,215,762.40. This represents a 58.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 3,236 shares of the firm's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the sale, the insider now directly owns 170,285 shares in the company, valued at approximately $4,728,814.45. This trade represents a 1.86% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 706,454 shares of company stock valued at $35,220,112. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Price Performance

HIMS stock traded down $1.55 during midday trading on Wednesday, reaching $41.40. The company had a trading volume of 62,607,390 shares, compared to its average volume of 22,646,900. The company has a market capitalization of $9.27 billion, a price-to-earnings ratio of 60.00, a price-to-earnings-growth ratio of 1.62 and a beta of 2.09. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The stock has a 50 day moving average price of $49.27 and a 200-day moving average price of $39.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.05 EPS. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on HIMS. Truist Financial dropped their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Citigroup reissued a "sell" rating and set a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Leerink Partners lifted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and an average price target of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.